COVID-19 Resource Center
COVID-19 Resource Center
Disclosures: Gutierrez reports he consults for Amgen and Janssen Pharmaceuticals. Please see the study for all other authors’ relevant financial disclosures.
April 06, 2021
1 min read
Save

COVID-19 confers elevated VTE risk in veterans

Disclosures: Gutierrez reports he consults for Amgen and Janssen Pharmaceuticals. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Among veterans hospitalized at Veterans Affairs facilities, patients with COVID-19 are at elevated risk for venous thromboembolism, according to a study published in the American Heart Journal.

“This study of patients at U.S. VA hospitals demonstrates that patients hospitalized with COVID-19, despite thromboprophylaxis, are at increased risk for VTE during admission and following discharge,” the researchers wrote.

Among veterans hospitalized at Veterans Affairs facilities, patients with COVID-19 are at elevated risk for venous thromboembolism. Data were derived from Gutierrez JA, et al. Am Heart J. 2021;doi:10.1016/j.ahj.2021.03.010.

The elevated risk is “potentially resulting from propagation of a consumptive coagulopathy due to activation of inflammatory pathways or via endotheliitis,” J. Antonio Gutierrez, MD, MHS, assistant professor of medicine at Duke University School of Medicine, and colleagues wrote.

The researchers analyzed 4,461 veterans who tested positive for COVID-19 and 76,929 with negative test results (median age, 68 years; 93% men) who were hospitalized at VA centers from May 1 to Aug. 1, 2020.

Researchers found that among patients with COVID-19, 9.2% had VTE compared with 6.8% of those without COVID-19 (P < .0001).

In patients with no history of VTE, 7.1% of those with COVID-19 experienced VTE compared with 4.6% in those without COVID-19 (P < .0001).

Among patients with COVID-19, 67.2% of VTE events happened during index hospitalization compared with 52.3% of those without COVID-19 (P < .0001).

After propensity score matching, patients with a positive COVID-19 test remained at elevated risk for VTE compared with those without one (HR = 1.28; 95% CI, 1.1-1.48; P = .001).

“This analysis adds to the mounting evidence of increased VTE risk in hospitalized patients with COVID-19 and extends our knowledge to now include increased risk following discharge. Furthermore, these results provide additional justification for future randomized controlled trials studying use of antithrombotics in hospitalized and convalescing patients with COVID-19,” the researchers wrote.